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Abstract
Integrating and expressing stably a transgene into the cellular genome remain major challenges for gene-based
therapies and for bioproduction purposes. While transposon vectors mediate efficient transgene integration,
expression may be limited by epigenetic silencing, and persistent transposase expression may mediate multiple
transposition cycles. Here, we evaluated the delivery of the piggyBac transposase messenger RNA combined with
genetically insulated transposons to isolate the transgene from neighboring regulatory elements and stabilize
expression. A comparison of piggyBac transposase expression from messenger RNA and DNA vectors was carried
out in terms of expression levels, transposition efficiency, transgene expression and genotoxic effects, in order to
calibrate and secure the transposition-based delivery system. Messenger RNA reduced the persistence of the
transposase to a narrow window, thus decreasing side effects such as superfluous genomic DNA cleavage. Both the
CTF/NF1 and the D4Z4 insulators were found to mediate more efficient expression from a few transposition events.
We conclude that the use of engineered piggyBac transposase mRNA and insulated transposons offer promising
ways of improving the quality of the integration process and sustaining the expression of transposon vectors.
Citation: Bire S, Ley D, Casteret S, Mermod N, Bigot Y, et al. (2013) Optimization of the piggyBac Transposon Using mRNA and Insulators: Toward a
More Reliable Gene Delivery System. PLoS ONE 8(12): e82559. doi:10.1371/journal.pone.0082559
Editor: Andrew C. Wilber, Southern Illinois University School of Medicine, United States of America
Received July 23, 2013; Accepted October 23, 2013; Published December 3, 2013
Copyright: © 2013 Bire et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the François Rabelais University of Tours and funded by grants from the European Commission
(SyntheGeneDelivery 018716), the CNRS, the French MENRT, the AFM (Grants 14020, 14509 and 15519), the GR CNRS 2157 and La Ligue Nationale
contre le cancer. Solenne Bire held a doctoral fellowship from the French MENRT. The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
* E-mail: solenne.bire@unil.ch (SB); florence.bonnin@univ-tours.fr (FR-B)
¤ Current address: Institute of Biotechnology, University of Lausanne, and Center for Biotechnology UNIL-EPFL, Lausanne, Switzerland
Introduction
For the purposes of gene therapy or bioproduction, stable
and long-lasting transgene expression is usually required. In
such case, stable integration of the transgene in the host
genome is often necessary. This may be achieved using
integrative viral or non-viral plasmid vectors. However, virus-
based vectors are immunogenic, they can cause genotoxic
effects, their cargo capacity is limited, and the large-scale
production of viral particles is complex [1]. DNA transposons
appear as a promising non-viral alternative: they have a greater
cargo capacity while maintaining highly efficient transgene
integration [2], and they are considered to be less
immunogenic than viral vectors [3]. Native DNA transposons
are mobile genetic elements encoding a single enzyme, the
transposase, which is able to recognize transposon-specific
inverted terminal repeats (ITRs) situated at both ends of the
transposon. Some transposases act to excise and reintegrate
the transposon at other sites in the genome by a “cut-and-
paste” mechanism. By replacing the transposase gene with a
gene of interest between the two ITRs, and by supplementing
the transposase source in trans, transposons have become
useful integrating vectors to reshape the genome of various
cells lines and organisms [4].
Among the eukaryotic transposons, Sleeping Beauty (SB)
has been the first shown to be active in human and mouse
cells [5,6]. SB has also been involved in preclinical trials [7], in
the perspective of human clinical trials. The piggyBac
transposon (PB), originally isolated from insect cells, was
recently added to the transposon toolbox for mammalian cell
engineering [8-10]. This element has the highest transposition
rates and cargo capacities in mammalian cell lines [11], and
PLOS ONE | www.plosone.org 1 December 2013 | Volume 8 | Issue 12 | e82559
the basic vector is relatively free from intellectual property
restrictions [12]. PB has been used for transgenesis in mice
[13], for gene transfer in human cells [14], and to reprogram
fibroblasts into induced pluripotent stem cells [15]. Moreover,
PB excises precisely upon transposition and would be less
susceptible to transposase overproduction inhibition or local
hopping than other transposons [13]. Optimized PB transposon
systems with more active transposases are also available
[16,17]. Finally, genome-wide integration analysis indicated
that PB has a slight bias towards integrating in cellular gene or
promoter sequences when compared to SB [18], suggesting an
increased risk of insertional genotoxicity for the former
transposon systems.
Transposition usually relies on the co-transfection of a donor
plasmid carrying the gene of interest and a helper plasmid
carrying the transposase gene under the control of a strong
promoter. The main drawback of this approach is the lasting
presence of the transposase due to the persistence of the
episomal plasmid DNA (pDNA). This in turn may lead to
multiple transposition cycles and thus increase potential
damages to the chromosome upon transposon excision and
chromosome break repair by cellular end-joining and
recombination activities. A more labile source of transposase,
such as messenger RNA (mRNA), should offer a more suitable
alternative to narrow the transposase expression and to
achieve more stable genomic integrations of the transgene,
while decreasing potential mutagenic effects [19]. Efficient
transposition using mRNA-encoded transposases has been
documented in various species including mammals [20,21].
Once integrated into a chromosome, transgenes may
undergo silencing epigenetic effects [22]. One way to
circumvent transgene extinction is to integrate chromatin-
control elements, such as insulators, into the transposon
cassette. Insulators are DNA cis-regulatory elements having
chromatin boundary and/or enhancer-blocker properties [23].
Boundary insulators prevent the propagation of a silencing
chromatin structure over the transgene, thus mediating higher
and/or more persistent levels of transgene expression.
Enhancer-blocker insulators specifically prevent the insertional
activation of adjacent cellular genes by the regulatory elements
of the vector and conversely. A lot of these sequences are
subjected to an extensive patenting since their discovery [24].
At present, several insulator sequences have been assessed in
various cellular or vector systems, including the cHS4, D4Z4,
CTCF and CTF/NF1 insulators [25-28]. However, a systematic
comparison of their potency is currently not available.
Using the piggyBac model, the aim of this study was to
improve the reliability and stability of gene transfer by the PB
transposon by delivering the source of transposase as an
mRNA and by integrating insulator elements in the transposon
cassette. We reduce the window time during which the
transposase is present in the cells and show that high
transposition efficiency can be achieved without detectable
genotoxicity. We identify insulating sequences that improve
expression of the transgene from just a few transposed vector
copies in human cells. Overall, we conclude that modulating
PB transposase bioavailability using exogenous mRNA and
insulating transposon-born transgenes offer a promising
approach to achieve both more secure transgene integration as
well as higher and more stable transgene expression.
Materials and Methods
Plasmid constructs
Helper plasmid.  The V5PB pDNA (6.4 kbp) encodes the V5
tagged PB transposase surrounded with the 5’ and 3’
untranslated terminal regions of the Xenopus laevis β-globin
gene and inserted into the pCS2+ vector (Life Technologies,
Paisley, UK). The V5PB sequence (2067 bp) did not contain
any AU-rich elements, 5’ stem loops, premature translation
termination codons or introns (GenBank accession number:
EF587698), and was synthesized by ATG:biosynthetic,
Merzhausen, Germany.
Donor plasmids.  pBSK ITR5'-NeoR-ITR3' (5.2 kbp) was
built by introducing the PB 3’ and 5’ inverted terminal repeats
(ITRs) (http://piggybac.bio.nd.edu/GenBank%20Format/pBSII-
ITR1.1k) into the pBluescript SK plasmid. The neomycin
phosphotransferase gene (NeoR, 1.5 kbp) was cloned between
the two ITRs. Two copies of the 1.2 kbp chicken ß-globin HS4
insulator (2xcHS4 2.4 kbp), one copy of the human core D4Z4
insulator (65 bp), six copies of the 40 bp CTCF binding site
(6xCTCF, 240 bp) or seven copies of the 20 bp CTF/NF1
binding site (7xCTF/NF1, 140 bp), were inserted on either side
of the transgene. The D4Z4 sequence was synthesized
according to patent application WO2009/016206.
Control plasmid.  The GFP pDNA (5.1 kbp) vector was built
by ligating the green fluorescent protein gene in the pCS2+. It
was used as a negative control of transposition (no
transposase).
In vitro mRNA synthesis
V5PB or GFP pDNA template preparation and in vitro
transcription was performed according to the Manufacturer’s
instructions using the MEGA Script SP6 kit combined with the
ARCA (Anti-Reverse Cap Analog) kit and polyadenylated using
the Poly(A) Tailing kit (Life Technologies). V5PB mRNA
(2.5 kb) and GFP mRNA (1.3 kb) were checked by 0.8%
agarose gel electrophoresis (Figure S1) and the concentration
was determined by measuring the absorbance at 260 nm.
Cell culture and nucleic acid transfection
HeLa cells (ATCC CCL-2) were cultured in DMEM-10% heat-
inactivated fetal bovine serum (PAA Laboratories, Pasching,
Austria) at 37°C and 5% CO2-containing atmosphere. The cells
were plated at a density of 1.105 cells per well in 24-well plates,
and grown for 24 h to 80% confluence. All transfections were
performed using jetPEI™ (Polyplus Transfection, Illkirch,
France) at an N/P ratio of 5 according to the Manufacturer's
instructions. When mRNA and pDNA were co-transfected,
complexes were formed separately.
Western-Blot
For the quantitative studies, cells were transfected with 0 to
500 ng of transposase encoding mRNA or pDNA and extracted
24 h post-transfection. For the kinetics of expression study,
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cells were transfected with 187.5 ng of V5PB mRNA or pDNA,
and extracted at various times. Transfected cells were
harvested with extraction buffer (0.5% SDS, 100-mM NaCl,
10 mM ß-mercaptoethanol and 1X protease inhibitor). 15 µg of
protein extract were loaded per lane on a 10% SDS–PAGE gel,
then transferred to a Hybond-ECLTM (GE Healthcare, Little
Chalfont, UK) membrane blocked with 5% non-fat dry milk
dissolved in PBS-Tween®20 0.05%. PB transposase (termed
V5PB Tp), Menin, β-actin or phosphorylated H2AX detection
was performed using specific antibodies dissolved in blocking
solution (Table S1) and using an ECLTM Western-Blot Analysis
System (GE Healthcare) and a LAS-4000 apparatus (Fujifilm,
Tokyo, Japan). Proteins were quantified using MultiGauge 4.0
software and normalized to an endogenous protein (Menin or
β-actin). Experiments were performed in triplicate.
Protein and nucleic half-life assays
PB mRNA.  Cells were transfected with 187.5 ng of V5PB
mRNA and total cellular RNA was extracted at different times
using the Nucleospin RNA II kit (Macherey-Nagel, Dueren,
Germany), reverse transcribed using the RevertAid First Strand
cDNA Synthesis kit (Roche Applied Science, Penzberg,
Germany), and subjected to real-time quantitative analysis on a
MiniOpticon Real-Time PCR System instrument and software
(Bio-Rad, Hercules CA, USA) with MesaGreen qPCR Master
Mix Plus for SYBR Assay NoRox kit (Eurogentec, Seraing,
Belgium). Reactions were performed in triplicate with specific
primers amplifying V5PB mRNA or 18S RNA (Table S2).
PB pDNA.  Cells were transfected with 187.5 ng of V5PB
pDNA and plasmid rescue assay was performed at different
times [29].
PB protein.  Cells were transfected with 187.5 ng of V5PB
transposase mRNA, incubated 18 h and then treated with
30 µg/mL of cycloheximide to shut down protein expression.
The decrease in protein was investigated by Western-Blot
analysis at different times.
Transposition assay
Cells were co-transfected with 0 to 500 ng of V5PB
transposase pDNA or mRNA and with equal amounts of donor
plasmid (1:1 ratio). Two days after transfection, cells were
transferred in 100-mm plates and selected with G418 sulfate
(800 µg/mL, PAA Laboratories) for 15 days. Cells were fixed
and stained with 70% EtOH-0.5% methylene blue and colonies
>0.5 mm in diameter were counted. To consider only
integration events due to transposition, the number of colonies
observed in the presence of the transposase source was
subtracted by the number of colonies obtained in the respective
negative control performed without transposase. Experiments
were performed in triplicate.
Copy number of genome integrated transgene or V5PB
transposase gene
After transposition assay, total DNA was isolated from stable
cell pools using the DNeasy Tissue Kit (Qiagen, Hilden,
Germany) according to the Manufacturer’s protocol. 10 ng of
genomic DNA were analyzed by quantitative PCR
(LightCycler1 480 real-time PCR system, Roche Applied
Science) using the SYBR Green-Taq polymerase kit
(Eurogentec) to amplify the NeoR, V5PB and GAPDH genes
(Table S2). The ratios of the NeoR and V5PB gene copy
numbers were calculated relative to that of the reference gene
GAPDH in the human genome. Reactions were performed in
triplicate.
Statistical analysis
Values are the mean ± standard deviation of experiments
done in triplicate. Shapiro-Wilk test confirmed the normality of
each set of samples. The significance of the differences
between groups with the control was tested using the Kruskal-
Wallis test with p<0.05.
Results
PB transposase expression from mRNA transfection
We first compared transposase expression in terms of
protein quantity and persistence from each type of nucleic acid
vector. The mRNA and pDNA vectors yielded dose-dependent
transposase expression levels during the first 24 h post-
transfection, reaching comparable maximal amounts in the
range tested (Figure 1A). However, the smaller amounts of
mRNA led to significantly less transposase than an equivalent
amount of pDNA (8-fold for 62.5 ng and 125 ng, p<0.05).
Therefore, the transposase expression levels could be
modulated by the quantity and type of nucleic acid transfected
in the cells, and high levels of expression could be reached by
transfecting high mRNA amounts, despite its lower efficacy on
a molar basis. In following experiments, 187.5 ng of mRNA or
pDNA was used to transfect cells, as these amounts yielded
comparable transposase levels. The kinetic of transposase
expression showed distinct patterns depending on the nucleic
acid transfected (Figure 1B). The pDNA led to little transposase
expression 5 h post-transfection, followed by a gradual rise to
reach a 10-fold increase 36 h post-transfection and a
plateauing effect at 48 h. Using mRNA, significant transposase
expression was observed after 5 h, further rising to reach a
peak at 18 h. Thereafter, transposase levels quickly declined to
background levels and only traces were detected at 48 h. Thus,
protein synthesis from an mRNA source was both faster and
more transitory than that obtained from the pDNA, as may be
expected.
Correspondingly, the half-life of the PB mRNA was estimated
to be ~3 h (Figure 2A). Only traces of mRNA were detected
36 h post-transfection, which is consistent with the decrease in
protein levels observed in Figure 1. The loss of pDNA following
transfection was much slower than that of the mRNA, as the
pDNA half-life was ~36 h and as it was still detectable 5 days
post-transfection (Figure 2B). The transposase bioavailability
was studied by determining the half-life of the protein. To do
so, cells were transfected with the PB mRNA and treated with
cycloheximide at the peak of transposase expression (18 h).
The decrease in transposase levels post-treatment showed a
half-life of ~12 h (Figure 2C), which is consistent with the sharp
decline of the transposase expressed from the mRNA vector
and from the short half-life of mRNA itself (Figure 1B and 2A).
Optimization of the piggyBac Transposon
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Overall, the mRNA provided a more restricted transposase
expression in terms of both quantity and duration.
PB mRNA-based transposition in mammalian cells
The functionality and efficiency of the transposase mRNA
source was assessed by performing transposition assays using
0 to 500 ng of transposase mRNA or pDNA vectors alongside a
fixed quantity of a circular donor plasmid (Figure 3A). In
Figure 1.  Expression (A) and kinetic (B) of PB transposase
by type and quantity of nucleic acid.  HeLa cells were
transfected with indicated amounts (A) or 187.5 ng (B) of PB
mRNA or pDNA and total protein extraction was performed
24 h (A) or at indicated times (B) post-transfection.
Transposase (V5PB Tp) expression was determined by
Western-Blot and protein quantification was normalized to the
endogenous Menin protein. Values represent the average of 3
experiments done in triplicate. Mock: untransfected cells. *
Indicates statistically significant differences between mRNA
and pDNA (p<0.05).
doi: 10.1371/journal.pone.0082559.g001
Figure 2.  piggyBac transposase bioavailability.  (A) Half-
life of the PB mRNA. Cells were transfected with 187.5 ng of
PB mRNA. Total RNA was extracted at indicated times,
reverse transcribed and subjected to qPCR. 18S RNA served
as an internal standard to normalize the data. (B) Persistence
of PB pDNA after transfection. Cells were transfected with
187.5 ng of PB pDNA and plasmid rescue was performed at 0
to 20 days. Ampicillin-resistant colonies were selected to
evaluate the persistence of the plasmid. (C) Half-life of the PB
transposase (V5PB Tp). Cells were transfected with 187.5 ng
of PB mRNA, incubated 18 h to reach the peak of transposase
expression and treated with cycloheximide (t0=100). Total
protein extraction was done at the indicated times from t0. The
transposase half-life was determined by Western-Blot and
quantification was normalized to the endogenous actin protein.
doi: 10.1371/journal.pone.0082559.g002
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presence of the transposase, a higher number of neomycin-
resistant stable colonies were scored using either the mRNA or
pDNA when compared to the negative control, indicating that
transposition had occurred in the cells (Figure 3B). The PB
transposase mRNA transfection also yielded a high number of
transposition events in another human cell line as well as in
CHO cells (Figure S2). The maximal number of transposition
events was obtained with 187.5 ng of pDNA and with 187.5
and 250 ng of mRNA, thus correlating well with the protein
expression profile (Figures 3 and 1). However, 3 to 5-fold fewer
colonies were scored using the mRNA (p<0.05). Quantification
of the integrated transgene copies revealed a mean number of
~2 transposable vectors per genome when using either the
transposase pDNA or the mRNA (Table 1, top line), implying
that the smaller colony number was not due to an intrinsically
lower transposition efficiency of the mRNA-expressed
transposase, and that it more likely resulted from the short
duration of expression. Indeed, transposition events probably
occurred mostly during the first 18 h after mRNA transfection,
whereas the pDNA-based transposition is expected to persist
for longer durations, thus increasing the likelihood of obtaining
at least one transposition event in a given cell. No integration of
the PB transposase gene was detected following mRNA
transfection, whereas pDNA transfection led to ~1.5 transgene
copies per cell, as resulting from the spontaneous
recombination events of one or several plasmids within a
genomic DNA locus (Table 1, bottom line). Therefore, the use
of mRNA transposase appears more reliable than the pDNA
approach to prevent potential secondary transposition cycles.
Impact of transposase expression and transposition on
cell viability
Transposases are known to allow specific DNA double-
strand breaks (DSBs) for excision and integration of the
transposon DNA. They may also mediate non-specific DSBs at
cryptic sites in the genome, which may lead to genotoxicity and
genomic damage [17]. We assayed the genotoxicity of the
transposase by transfecting varying amounts of PB mRNA or
pDNA and detecting phosphorylated H2AX (γ-H2AX) as a
marker of DSB DNA damages (Figure 4). Untransfected cells
(Mock) displayed a basal γ-H2AX signal due to constitutive
DSBs occurring spontaneously in the cultured cells (dotted
line). The T-GFP control showed a slight increase in the γ-H2AX
signal (dashed line), due to DSBs-like structures on the
transfected nucleic acids. mRNA and pDNA led to a similar γ-
H2AX pattern since comparable amounts of transposase were
produced at the DSB quantification time (24 h, Figure 1). No
statistical difference in the γ-H2AX signal was observed using
≤187.5 ng of PB mRNA or pDNA whereas higher quantities
induced γ-H2AX increase comparable to the doxorubicin-
treated positive control. So, the amount of transposase
produced from ≤187.5 ng of mRNA or pDNA does not result in
detectable cytotoxic effects. This result was confirmed using a
cell metabolism and proliferation assay (Figure S3), showing
that neither transfection nor the presence of the transposase
and resulting transposition events affected cell viability under
these conditions.
Figure 3.  Transposition assay in mammalian cells.  (A)
Donor plasmid harboring the transposable element. This vector
is composed of the neomycin phosphotransferase gene (NeoR)
flanked by the PB ITRs. (B) Transposition efficiency by type
and quantity of nucleic acid. Cells were transfected with
indicated amounts of PB mRNA or pDNA alongside with
187.5 ng of donor plasmid. GFP mRNA or pDNA (500 ng)
served as negative controls of transposition (Mock:
recombination events). To consider only transposition events,
the number of colonies observed in the presence of the
transposase source was subtracted by the number of colonies
obtained in the respective negative control performed without
transposase for each quantity. Values represent the average of
3 experiments done in triplicate. * Represents statistically
significant difference between mRNA and pDNA (p<0.05).
doi: 10.1371/journal.pone.0082559.g003
Table 1. Number of transgene or piggyBac gene
integrations in pools of colonies in the presence of a pDNA
or mRNA source of the V5PB transposase.
 V5PB pDNA V5PB mRNA
Mean number of transposon integrations in pools of
colonies 2.2 1.9
Mean number of transposase gene integrations in
pools of colonies 1.5 0
doi: 10.1371/journal.pone.0082559.t001
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Use of insulator sequences to isolate the transgene
from the surrounding environment
To prevent frequent post-integrative transcriptional silencing
of the transgene, the transposable NeoR cassette was
bracketed with the cHS4, D4Z4, CTCF and CTF/NF1
insulators, and these constructs were assayed in transposition
assays (Figure 5A). To find out whether insulators mediated
position-effect protection and/or affected the transposition or
spontaneous recombination rate, the transgene copy number
was also estimated, since cells harboring silenced transgenes
may not form colonies under antibiotic selection. All the
constructs led to transposition events (Figure 5B, left panel).
The cHS4 insulator gave similar colony and transgene copy
numbers as the non-insulated control in the presence of
transposase (Figure 5C). However, the recombination control
showed a higher colony number (Figure 5B, right panel) and 4-
fold more insertions. Therefore, cHS4 may have insulator effect
when copies are integrated by recombination, which often led
to tandem insertions, but to a lesser extent in the case of
transposition (one copy per locus). Transposition assays
performed using equimolar amounts of the non-insulated and
cHS4 insulated donor vectors, to consider the larger size of the
cHS4 plasmid, gave comparable results (Figure S4). In the
presence of the PB pDNA or mRNA, the D4Z4 element
Figure 4.  Detection of H2AX phosphorylation following
dose-dependent PB mRNA or pDNA transfection.  Cells
were transfected with indicated amounts of PB mRNA or pDNA
and total protein extraction was performed 24 h post-
transfection. γ-H2AX expression was determined by Western-
Blot and protein quantification was normalized to the
endogenous Menin protein. Mock: untransfected cells. T-GFP:
cells transfected with 500 ng of GFP mRNA or pDNA. T+:
untransfected cells treated with 2 µg/mL doxorubicin (positive
control). * Indicates statistically significant differences between
treated and untreated cells (p<0.05). Values represent the
average of 3 experiments done in triplicate. The signal between
the dotted line (mock control) and solid line (T-GFP control) is
considered to be due to the “transfection effect”. Above the
solid line, the signal is due to the “transposase effect”.
doi: 10.1371/journal.pone.0082559.g004
respectively increased the number of colonies by 2- and 3.4-
fold, and the CTF/NF1 by 2.5- and 2.4-fold. Since the D4Z4,
CTF/NF1 and non-insulated NeoR constructs showed
equivalent NeoR copy number with or without transposase, the
increase in colony number was probably due to insulating
protection rather than a more efficient transposition (or
recombination). Thus, the D4Z4 and CTF/NF1 elements had
insulator functions when combined with transposition. The
CTCF reduced the number of colonies by 3-fold in the
presence of transposase even though numerous transposons
were integrated (>17 copies). This element was probably acting
as a silencer by inhibiting the transgene transcription or by
epigenetic silencing, rather than influencing transgene
mobilization.
Discussion
Limiting or cutting-off transposase expression is a major
challenge to enhance the biosafety of transposon-based gene
delivery tools [30]. Several alternatives are investigated to
control transposase expression in terms of quantity and
duration: (i) inducible transposase expression [16], (ii) self-
inactivating systems [31], (iii) delivery of a purified transposase
[32]. However, these strategies are limited: pDNA-based
systems pose the issue of transposase gene recombination in
the cellular genome; active transposase proteins are not easy
and expensive to produce. In this study, we focused on
providing the transposase as an mRNA to control the
transposase expression and ensure irreversible transgene
integration. In vitro-transcribed mRNAs were successfully used
with various transposon [20,21,33]. Here, a step-by-step
comparison between PB mRNA and pDNA was carried out for
the first time in terms of transposase expression, transposition
efficiency and genotoxic effects in order to calibrate and secure
the system.
The transfected PB mRNA led to a narrow window of
expression and fewer transposition events due to its short half-
life, compared to the mean half-life of endogenous human
mRNAs (10 h, [34]), and that the proportion of mRNA
potentially kept in cytoplasmic granules is not sufficient to allow
prolonged protein expression [35]. Although theoretically
impossible, a few cases of mRNA insertion through chimeric
retropseudogenes have been reported [36], but their
functionality has not been demonstrated. In our experiments,
no integration was detected following PB mRNA transfection. In
contrast, episomal pDNA and transposase gene integrations
were detected following plasmid transfection, confirming that
mRNA provides a decisive advantage in limiting transposase
expression. Compared to other transposases [37] or related
proteins [38], the PB transposase has a long half-life. As far as
we are aware, this is the first time that a eukaryotic
transposase mRNA and protein half-lives have been
calculated, although these are essential milestones for
monitoring transposase bioavailability and transposition events.
Neither small amounts of mRNA or pDNA transposase, nor
transposition events caused major cell damage or cytotoxicity,
indicating that the DNA damage cellular response was not
overwhelmed [17]. Moreover, transposon systems were found
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Figure 5.  Effect of the insulating sequences.  (A) Donor plasmids used for the insulator-effect study. The cHS4, D4Z4, CTCF or
CTF/NF1 elements were cloned on either side of the NeoR transgene. (B) Analysis of the different insulated vectors in in vitro colony
forming assays in presence (left panel) or absence (right panel) of transposase. Cells were transfected with 187.5 ng of PB pDNA or
mRNA plus 187.5 ng of each insulated donor plasmid (left panel). To consider only transposition events, the number of colonies
observed in the presence of the transposase source was subtracted by the number of colonies obtained in the respective negative
control performed without transposase for each quantity (right panel). Values represent the average of 3 experiments done in
triplicate. * Indicates statistically significant differences between the non-insulated and the insulated NeoR transposons (p<0.05). (C)
Impact of the insulating sequences on the transgene copy number in pools of colonies. qPCR was performed on genomic DNA from
pools of colonies with NeoR specific primers. The mean copy number was calculated relative to that of the reference gene GAPDH
in the human genome. * Indicates statistically significant differences between the non-insulated and the insulated NeoR transposons
(p<0.05). White bars correspond to plasmid transfection performed in the absence of the piggyBac transposase.
doi: 10.1371/journal.pone.0082559.g005
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less genotoxic than other non-viral integrative systems such as
the ϕC31 integrase [39]. As reported earlier, our PB
transposon integrated only few copies of the transgene thus,
limiting insertional mutations [40]. Consequently, this
transposon system appears to be safer than the other
technologies and could be further optimized by mRNA
engineering.
Once integrated, the gene of interest must be properly
expressed, but newly integrated transgenes can be rapidly
silenced by the host machinery [22]. A first strategy to
circumvent silencing is to target high and continuous gene
expression sites (reviewed in 41). A second solution is to use
hyperactive transposases to increase the number of transgene
insertions [17], but this also enhances the risk of insertional
mutagenesis. The third solution is to use insulators to isolate
the transgene from its surrounding environment. Insulators act
as genetic barriers preventing deleterious
heterochromatinization or activation of regulatory elements of
the transgene but also of nearby cellular genes [42]. The
insulated transgene is expected to behave as an
autonomously-regulated expression unit [27].
In our hands, the cHS4 insulator did not improve the PB
system. This insulator has been shown to be efficient when
combined with transposon vectors, but cHS4 is also known not
to provide absolute protection and to be functional in only
certain cell types [25]. The transgene size effect could be ruled
out since PB is able to efficiently mobilize large transposons
[11]. The D4Z4 and CTF/NF1 minute elements led to a
doubling of the colony number with no increase in the
transgene copy number, suggesting a protective effect on
transgene expression, as described previously [27,28]. This is
consistent with other experiments performed with Sleeping
Beauty, demonstrating that insulators did not affect pDNA
transport or transposon mobilization, but only influenced
transgene expression following integration into chromosomal
chromatin, i.e. by preventing silencing effects and/or by directly
activating the transcription of the transgene [25].
Overall, engineered transposase mRNA and insulated
transposons could improve the quality of the transposition
process and the quality of the transgene expression without
increasing the number of inserted transgenes. It will be
interesting to further assess the use of transposase mRNA and
insulated transposons in the context of ex vivo gene or cell
therapies, or the production of factory cells by generating
genetically stable and efficient master cell banks.
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Table S1.  Antibodies used in these study.
(PDF)
Table S2.  Names and sequences of the primers used in
these study.
(PDF)
Figure S1.  Control of in vitro synthesized mRNA quality.
Quality and effective polyadenylation of mRNA (pA) were
checked on 0,8% agarose gel electrophoresis. Before loading,
mRNA was denatured during 10 min at 65°C.
(PDF)
Figure S2.  mRNA piggyBac-based transfection is efficient
in various mammalian cell lines. 1.105 HEK 293 cells (upper
panel) or CHO cells (lower panel) were transfected with 200 ng
of V5PB mRNA alongside with a donor plasmid carrying the
neomycin resistance gene (200 ng). After 15 days under
antibiotic selection, resistant colonies were stained and
counted to attest transposition efficiency. GFP mRNA (200 ng)
served as a negative control (Mock=without transposase)
corresponding to recombination events. Data are a
representative image of 3 experiments done in triplicate.
(PDF)
Figure S3.  Cell proliferation assay after transfection
and/or transposition assay. 104 cells were transfected with
187.5 ng of V5PB or GFP mRNA or pDNA, and/or with
187.5 ng of pBSK ITR-NeoR-ITR. GFP mRNA and pDNA were
both used to exclude any impact of the gene sequence on the
test results. Cell proliferation was assayed 24 h (dark grey
bars) and 48 h (light grey bars) post-transfection by performing
an MTT assay according to the Manufacturer’s instructions
(CellTiter96® Non-Radioactive Proliferation assay, Promega,
Madison WI, USA). The cell propagation was calculated by
subtracting the absorption at 650 nm (background absorbance)
from the absorption at 595 nm (sample absorbance). The
propagation of non-transfected cells was taken to be 100%.
Values represent the mean ± SD (n=4). PEI: jetPEI only treated
cells. No statistical difference in the signal was observed
between the mock control and the other conditions using the
Kruskal-Wallis test with p<0.05.
(PDF)
Figure S4.  Transposition assay using equimolar amount
of the uninsulated and cHS4 insulated Neo plasmids. To
consider the large size of the cHS4 sequence and to transfect
the same number of plasmid molecules, transposition assays
were performed using 200 ng of pBSK ITR5’-NeoR-ITR3’ (black
bars) or 400 ng of pBSK ITR5’-2xcHS4-NeoR-2xcHS4-ITR3’
(grey bars), alongside with 200 ng of the V5PB mRNA or GFP
mRNA (negative control). Resistant colonies were stained with
70%EtOH-methylene blue and counted. The figure represents
data of three experiments done in triplicate.
(PDF)
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